IHS Chemical Week

Regions :: Middle East

Lonza and Teva reaffirm commitment to biosimilars joint venture

10:09 AM MDT | April 5, 2013 | Deepti Ramesh

Lonza and Teva Pharmaceutical (PetaŠł• Tiqwa, Israel) say that the potential to develop, manufacture, and market affordable, efficacious, and safe biosimilars remains an area of significant opportunity for both companies. The announcement follows recent press reports which suggest that the future of their previously announced biosimilars joint venture is doubtful. Lonza and Teva agreed in 2009 to establish a jv to develop, manufacture, and market a portfolio of biosimilars. Richard Ridinger, Lonza CEO, in a recent interview with a Swiss business newspaper...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers

 

 

 













 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2012 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa